82.36 USD
-0.31 (-0.37%)
Taking everything into account, ANIP scores 6 out of 10 in our fundamental rating. ANIP was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ANIP get a neutral evaluation. Nothing too spectacular is happening here. ANIP has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, ANIP could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
ANIP had positive earnings in the past year.
ANIP had a positive operating cash flow in the past year.
ANIP had negative earnings in 4 of the past 5 years.
Of the past 5 years ANIP 4 years had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 2.42%, ANIP belongs to the best of the industry, outperforming 82.81% of the companies in the same industry.
ANIP has a better Return On Equity (6.75%) than 84.90% of its industry peers.
ANIP has a better Return On Invested Capital (5.60%) than 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.42% | ||
| ROE | 6.75% | ||
| ROIC | 5.6% |
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 4.13%, ANIP belongs to the best of the industry, outperforming 81.77% of the companies in the same industry.
ANIP has a better Operating Margin (9.75%) than 82.29% of its industry peers.
In the last couple of years the Operating Margin of ANIP has declined.
ANIP has a Gross Margin of 61.14%. This is in the better half of the industry: ANIP outperforms 70.31% of its industry peers.
In the last couple of years the Gross Margin of ANIP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.75% | ||
| PM (TTM) | 4.13% | ||
| GM | 61.14% |
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ANIP is destroying value.
Compared to 1 year ago, ANIP has more shares outstanding
Compared to 5 years ago, ANIP has more shares outstanding
Compared to 1 year ago, ANIP has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.33 indicates that ANIP is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.33, ANIP is doing good in the industry, outperforming 63.54% of the companies in the same industry.
ANIP has a debt to FCF ratio of 3.98. This is a good value and a sign of high solvency as ANIP would need 3.98 years to pay back of all of its debts.
ANIP has a better Debt to FCF ratio (3.98) than 84.90% of its industry peers.
ANIP has a Debt/Equity ratio of 1.20. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.20, ANIP is doing worse than 73.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.2 | ||
| Debt/FCF | 3.98 | ||
| Altman-Z | 2.33 |
ROIC/WACC0.63
WACC8.88%
2.3 Liquidity
A Current Ratio of 2.58 indicates that ANIP has no problem at all paying its short term obligations.
With a Current ratio value of 2.58, ANIP perfoms like the industry average, outperforming 45.31% of the companies in the same industry.
ANIP has a Quick Ratio of 2.04. This indicates that ANIP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ANIP (2.04) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.58 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
ANIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.89%, which is quite impressive.
The Earnings Per Share has been growing slightly by 0.59% on average over the past years.
Looking at the last year, ANIP shows a quite strong growth in Revenue. The Revenue has grown by 19.34% in the last year.
Measured over the past years, ANIP shows a very strong growth in Revenue. The Revenue has been growing by 24.37% on average per year.
EPS 1Y (TTM)56.89%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%52.24%
Revenue 1Y (TTM)19.34%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%53.58%
3.2 Future
ANIP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.43% yearly.
The Revenue is expected to grow by 14.35% on average over the next years. This is quite good.
EPS Next Y42.82%
EPS Next 2Y25.67%
EPS Next 3Y21.92%
EPS Next 5Y17.43%
Revenue Next Year40.97%
Revenue Next 2Y24.33%
Revenue Next 3Y19.12%
Revenue Next 5Y14.35%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 11.49, the valuation of ANIP can be described as very reasonable.
89.58% of the companies in the same industry are more expensive than ANIP, based on the Price/Earnings ratio.
ANIP is valuated cheaply when we compare the Price/Earnings ratio to 26.37, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 10.03, the valuation of ANIP can be described as very reasonable.
ANIP's Price/Forward Earnings ratio is rather cheap when compared to the industry. ANIP is cheaper than 86.46% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.20. ANIP is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.49 | ||
| Fwd PE | 10.03 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ANIP indicates a rather cheap valuation: ANIP is cheaper than 83.33% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ANIP is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.88 | ||
| EV/EBITDA | 12.78 |
4.3 Compensation for Growth
ANIP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ANIP may justify a higher PE ratio.
A more expensive valuation may be justified as ANIP's earnings are expected to grow with 21.92% in the coming years.
PEG (NY)0.27
PEG (5Y)19.56
EPS Next 2Y25.67%
EPS Next 3Y21.92%
5. Dividend
5.1 Amount
ANIP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ANIP (12/4/2025, 12:54:16 PM)
82.36
-0.31 (-0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners93.3%
Inst Owner Change2.18%
Ins Owners7.14%
Ins Owner Change-4.29%
Market Cap1.85B
Revenue(TTM)826.88M
Net Income(TTM)34.14M
Analysts84.29
Price Target111.33 (35.17%)
Short Float %12.99%
Short Ratio6.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP4.58%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.16%
Min EPS beat(2)14.04%
Max EPS beat(2)24.28%
EPS beat(4)4
Avg EPS beat(4)17.56%
Min EPS beat(4)11.36%
Max EPS beat(4)24.28%
EPS beat(8)8
Avg EPS beat(8)16.28%
EPS beat(12)12
Avg EPS beat(12)41.62%
EPS beat(16)13
Avg EPS beat(16)13.52%
Revenue beat(2)2
Avg Revenue beat(2)7.37%
Min Revenue beat(2)5.83%
Max Revenue beat(2)8.9%
Revenue beat(4)4
Avg Revenue beat(4)7.06%
Min Revenue beat(4)5.83%
Max Revenue beat(4)8.9%
Revenue beat(8)8
Avg Revenue beat(8)5.8%
Revenue beat(12)12
Avg Revenue beat(12)9.19%
Revenue beat(16)15
Avg Revenue beat(16)7.44%
PT rev (1m)5.38%
PT rev (3m)14.2%
EPS NQ rev (1m)0.52%
EPS NQ rev (3m)0.49%
EPS NY rev (1m)0.1%
EPS NY rev (3m)0.75%
Revenue NQ rev (1m)2.77%
Revenue NQ rev (3m)3.82%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)0.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.49 | ||
| Fwd PE | 10.03 | ||
| P/S | 2.24 | ||
| P/FCF | 11.88 | ||
| P/OCF | 10.84 | ||
| P/B | 3.66 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.78 |
EPS(TTM)7.17
EY8.71%
EPS(NY)8.21
Fwd EY9.97%
FCF(TTM)6.93
FCFY8.42%
OCF(TTM)7.6
OCFY9.22%
SpS36.8
BVpS22.51
TBVpS-2.51
PEG (NY)0.27
PEG (5Y)19.56
Graham Number60.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.42% | ||
| ROE | 6.75% | ||
| ROCE | 7.09% | ||
| ROIC | 5.6% | ||
| ROICexc | 7.35% | ||
| ROICexgc | 20.96% | ||
| OM | 9.75% | ||
| PM (TTM) | 4.13% | ||
| GM | 61.14% | ||
| FCFM | 18.83% |
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-44.22%
ROICexc growth 3YN/A
ROICexc growth 5Y-46.62%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
F-Score7
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.2 | ||
| Debt/FCF | 3.98 | ||
| Debt/EBITDA | 3.52 | ||
| Cap/Depr | 16.39% | ||
| Cap/Sales | 1.81% | ||
| Interest Coverage | 2.94 | ||
| Cash Conversion | 99.25% | ||
| Profit Quality | 456.13% | ||
| Current Ratio | 2.58 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 2.33 |
F-Score7
WACC8.88%
ROIC/WACC0.63
Cap/Depr(3y)17.9%
Cap/Depr(5y)14.57%
Cap/Sales(3y)2.42%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.89%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%52.24%
EPS Next Y42.82%
EPS Next 2Y25.67%
EPS Next 3Y21.92%
EPS Next 5Y17.43%
Revenue 1Y (TTM)19.34%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%53.58%
Revenue Next Year40.97%
Revenue Next 2Y24.33%
Revenue Next 3Y19.12%
Revenue Next 5Y14.35%
EBIT growth 1Y278.34%
EBIT growth 3YN/A
EBIT growth 5Y-34.31%
EBIT Next Year46.79%
EBIT Next 3Y23.35%
EBIT Next 5Y18.44%
FCF growth 1Y159.17%
FCF growth 3Y297.63%
FCF growth 5Y4.15%
OCF growth 1Y144.51%
OCF growth 3Y168.16%
OCF growth 5Y7.01%
ANI PHARMACEUTICALS INC / ANIP FAQ
What is the fundamental rating for ANIP stock?
ChartMill assigns a fundamental rating of 6 / 10 to ANIP.
What is the valuation status of ANI PHARMACEUTICALS INC (ANIP) stock?
ChartMill assigns a valuation rating of 9 / 10 to ANI PHARMACEUTICALS INC (ANIP). This can be considered as Undervalued.
Can you provide the profitability details for ANI PHARMACEUTICALS INC?
ANI PHARMACEUTICALS INC (ANIP) has a profitability rating of 6 / 10.
Can you provide the financial health for ANIP stock?
The financial health rating of ANI PHARMACEUTICALS INC (ANIP) is 5 / 10.
Can you provide the expected EPS growth for ANIP stock?
The Earnings per Share (EPS) of ANI PHARMACEUTICALS INC (ANIP) is expected to grow by 42.82% in the next year.